1. Home
  2. ICCC vs NSRX Comparison

ICCC vs NSRX Comparison

Compare ICCC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$6.27

Market Cap

55.5M

Sector

Health Care

ML Signal

N/A

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$5.90

Market Cap

63.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICCC
NSRX
Founded
1982
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.5M
63.4M
IPO Year
1987
2025

Fundamental Metrics

Financial Performance
Metric
ICCC
NSRX
Price
$6.27
$5.90
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.50
AVG Volume (30 Days)
25.5K
6.5K
Earning Date
02-25-2026
02-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$27,769,304.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.27
N/A
Revenue Growth
16.49
N/A
52 Week Low
$4.28
$5.50
52 Week High
$7.60
$9.99

Technical Indicators

Market Signals
Indicator
ICCC
NSRX
Relative Strength Index (RSI) 52.97 39.11
Support Level $6.15 $5.50
Resistance Level $6.92 $7.70
Average True Range (ATR) 0.33 0.43
MACD -0.05 -0.15
Stochastic Oscillator 31.82 15.84

Price Performance

Historical Comparison
ICCC
NSRX

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: